Promoter Hypermethylation of Tumour Suppressor Genes As Potential Biomarkers in Colorectal Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2015 Jan 27

PMID 25622259

Citations 85

Authors

Jennifer Mun-Kar Ng

Jun Yu

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is a common malignancy and the fourth leading cause of cancer deaths worldwide. It results from the accumulation of multiple genetic and epigenetic changes leading to the transformation of colon epithelial cells into invasive adenocarcinomas. In CRC, epigenetic changes, in particular promoter CpG island methylation, occur more frequently than genetic mutations. Hypermethylation contributes to carcinogenesis by inducing transcriptional silencing or downregulation of tumour suppressor genes and currently, over 600 candidate hypermethylated genes have been identified. Over the past decade, a deeper understanding of epigenetics coupled with technological advances have hinted at the potential of translating benchtop research into biomarkers for clinical use. DNA methylation represents one of the largest bodies of literature in epigenetics, and hence has the highest potential for minimally invasive biomarker development. Most progress has been made in the development of diagnostic markers and there are currently two, one stool-based and one blood-based, biomarkers that are commercially available for diagnostics. Prognostic and predictive methylation markers are still at their infantile stages.

Citing Articles

Data-Driven Identification of Early Cancer-Associated Genes via Penalized Trans-Dimensional Hidden Markov Models.

Hajebi Khaniki S, Shokoohi F Biomolecules. 2025; 15(2).

PMID: 40001597 PMC: 11853217. DOI: 10.3390/biom15020294.

Nicotinamide mononucleotide protects STAT1 from oxidative stress-induced degradation to prevent colorectal tumorigenesis.

Li T, Luo C, Liu Z, Li J, Han M, Zhang R MedComm (2020). 2024; 5(12):e70006.

PMID: 39575303 PMC: 11581775. DOI: 10.1002/mco2.70006.

Unmasking early colorectal cancer clues: in silico and in vitro investigation of downregulated IGF2, SOCS1, MLH1, and CACNA1G in SSA polyps.

Mirbahari S, Fatemi N, Savabkar S, Chaleshi V, Zali N, Taleghani M Mol Biol Rep. 2024; 51(1):764.

PMID: 38874740 PMC: 11178608. DOI: 10.1007/s11033-024-09683-3.

Colorectal cancer microbiome programs DNA methylation of host cells by affecting methyl donor metabolism.

Liu Z, Zhang Q, Zhang H, Yi Z, Ma H, Wang X Genome Med. 2024; 16(1):77.

PMID: 38840170 PMC: 11151592. DOI: 10.1186/s13073-024-01344-1.

Associations in cell type-specific hydroxymethylation and transcriptional alterations of pediatric central nervous system tumors.

Lee M, Azizgolshani N, Zhang Z, Perreard L, Kolling F, Nguyen L Nat Commun. 2024; 15(1):3635.

PMID: 38688903 PMC: 11061294. DOI: 10.1038/s41467-024-47943-9.

References

Issa J . CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004; 4(12):988-93. DOI: 10.1038/nrc1507. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Song B, Jain S, Lin S, Chen Q, Block T, Song W . Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J Mol Diagn. 2012; 14(2):112-9. PMC: 3349838. DOI: 10.1016/j.jmoldx.2011.12.003. View

Liang G, Salem C, Yu M, Nguyen H, Gonzales F, Nguyen T . DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics. 1998; 53(3):260-8. DOI: 10.1006/geno.1998.5502. View

Zou H, Harrington J, Shire A, Rego R, Wang L, Campbell M . Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev. 2007; 16(12):2686-96. DOI: 10.1158/1055-9965.EPI-07-0518. View

Imperiale T, Ransohoff D, Itzkowitz S . Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014; 371(2):187-8. DOI: 10.1056/NEJMc1405215. View

Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner G, Weisenberger D . CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006; 55(7):1000-6. PMC: 1856352. DOI: 10.1136/gut.2005.082933. View

Yoo C, Jones P . Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006; 5(1):37-50. DOI: 10.1038/nrd1930. View

Rex D, Ahnen D, Baron J, Batts K, Burke C, Burt R . Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012; 107(9):1315-29. PMC: 3629844. DOI: 10.1038/ajg.2012.161. View

10.

Dong S, Traverso G, JOHNSON C, Geng L, Favis R, Boynton K . Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001; 93(11):858-65. DOI: 10.1093/jnci/93.11.858. View

11.

Widschwendter M, Siegmund K, Muller H, Fiegl H, Marth C, Muller-Holzner E . Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004; 64(11):3807-13. DOI: 10.1158/0008-5472.CAN-03-3852. View

12.

Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L . A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 2008; 103(11):2862-70. DOI: 10.1111/j.1572-0241.2008.02088.x. View

13.

Bardhan K, Liu K . Epigenetics and colorectal cancer pathogenesis. Cancers (Basel). 2013; 5(2):676-713. PMC: 3730326. DOI: 10.3390/cancers5020676. View

14.

Hinoue T, Weisenberger D, Lange C, Shen H, Byun H, van den Berg D . Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2011; 22(2):271-82. PMC: 3266034. DOI: 10.1101/gr.117523.110. View

15.

Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner G . LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer. 2008; 122(12):2767-73. PMC: 2630175. DOI: 10.1002/ijc.23470. View

16.

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

17.

Kristensen L, Mikeska T, Krypuy M, Dobrovic A . Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res. 2008; 36(7):e42. PMC: 2367707. DOI: 10.1093/nar/gkn113. View

18.

Barault L, Charon-Barra C, Jooste V, Vega M, Martin L, Roignot P . Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008; 68(20):8541-6. DOI: 10.1158/0008-5472.CAN-08-1171. View

19.

Toyota M, Ahuja N, Herman J, Baylin S, Issa J . CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999; 96(15):8681-6. PMC: 17576. DOI: 10.1073/pnas.96.15.8681. View

20.

Grady W, Rajput A, Lutterbaugh J, Markowitz S . Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 2001; 61(3):900-2. View